BREAKING NEWS - Ally Bridge Group, KCK MedTech, Questa Capital and OrbiMed

Quote

anonymous

Guest
Every dollar of your investments in

Aerin Medical

is being utilized to hire friends of current leadership and falsely build an infrastructure of salaries and titles but there will be no results.

nor buyout! Your investment dollars are being bled out like a slaughter.

35% of the customer base prior has stopped ordering 100% because of being misled by upper leadership in commercial coverage. They are never going to receive commercial insured coverage. Never!

Market Access leadership is being forced to flat out lie about their covered lives and Medicare is the only payor.

Better pricing models for ablation are here now. The over priced wand is not novel and is nothing more than a slightly better breath right strip.

Your investment is tanking and there is no rebound comeback.

Time to cut bait. Stop listening to the lies at the BOD meetings. Hire an attorney to consult.
 




The spend on the fake Reimbursement Center is over 200,000$ a month where appeals have absolutely no success and the only wins with over 2600 claims are within Medicare and Medicare advantage.

the strategy of pressuring the commercial payor’s with the ARC reimbursement center is a complete failure. Complete wasted $$$$ strategy.

we have more overhead in leadership titles than necessary. Investor money is being spent freely with infrastructure that brings absolutely no value.
 




Aerin Medical does not provide transparency of true reimbursement when promoting this device.

The commercial payor collectively will never pay their new code plus the other ancillary codes. The ancillary codes are all under major scrutiny. Medicare is the only payor and that is in jeopardy as well.

Aerin price hiked VivAer and RhinAer to show revenue to investors but they have lost 10-15% of their primary customer base amounting to 30% loss in actual physical inventory sales. They are burning through 2022 capital provided by the named investors at a high rate with false implied infrastructure of growth.

It is a losing proposition where a buyout is not a profitable option. There is no pipeline. This is a one trick pony of tissue shrink ablation.
Payor’s are not going to pay 4,000$ for nasal tissue shrink ablation.

One more note. Aerin’s top KOL’s have written off thousands of dollars in lost non existent reimbursement revenue to VivAer and RhinAer. Loyalty is growing thin.
 




Brokaw lied over two years promising 65% commercial coverage. They have 2% commercial coverage and all reviews are finished for a minimum of 8 months to a full year.

Brokaw is a talking head who has absolutely low acumen of reimbursement policy in the US market. False representation for personal gain.
 












So Aerin has a VP of Medical Policy and a Reimbursement Director. Special location Director. Reimburse managers (worthless)
And now they are going to a Director of Medical Policy.

you fool investors. They are burning your cash so bad. LOL
 








Top Bottom
Back
Quote